Bioscience Reports

The R2TP is a multimeric protein complex consists of RUVBL1, RUVBL2, PIH1D1, and RPAP3, and it is known to functions as a specialized co-chaperone. We hypothesize that PIH1D1 recognizes p53 and stabilizes it via R2TP complex. Upon successful completion of this study, innovative mechanism has been found for the interaction and stabilization of p53 and hence govern the cell cycle. Upon interaction between p53 and PIH1D1 protein, p53 is stabilized by PIH1D1 protein, without affecting its C-terminal domain. We have also observed that p53 protein levels were affected after the alteration in expression levels of PIH1D1. Based on the finding, we suggest that the R2TP complex stabilizes and regulates P53. Therefore, this novel method will work as a flashpoint to restore the function of p53 in cancer cells, controlling cancer and cell cycle progression.

The Ube2J1 enzyme that mediates the ubiquitination and proteasomal degradation of misfolded proteins at the ER is phosphorylated at serine S184. Following anisomycin treatment of HEK293T cells, we observed an inverse relationship between phosphorylation and dephosphorylation at this site. This suggested a dynamic interchange between the two forms, and we show that S184 is a target for protein phosphatase 2A. The S184-phosphorylated protein is known to exhibit increased sensitivity to proteasomal degradation, and we found that mutation at K186R increased the ratio of S184-phosphorylated to S184-dephosphorylated protein. Although the K186R mutant retained some sensitivity to proteasomal inhibition, our results show that Ube2J1 steady state expression can be exercised at multiple levels, and can involve dynamic phosphorylation and dephosphorylation at S184.

Many people are affected by post-acute sequelae of COVID-19 (PASC/long COVID, LC). LC has severely affected public health. Features of LC including blood pressure dysregulation, coagulopathies, hyperinflammation, and neuropsychiatric complaints. Mechanisms responsible for LC pathogenesis are not clear. The receptor for SARS-CoV-2 is human angiotensin converting enzyme 2 (ACE2), which binds SARS-CoV-2 spike protein receptor-binding domain (RBD) to initiate infection. We hypothesized that some people produce anti-RBD antibodies that sufficiently resemble ACE2 structure to have ACE2-like catalytic activity. Those antibodies, ACE2-like abzymes, may contribute to LC pathogenesis. We previously showed that ACE2-like activity was associated with immunoglobulin in some people with acute and convalescent COVID-19. ACE2-like catalytic activity correlated with blood pressure changes following moderate exercise challenge in convalescents. We screened human monoclonal antibodies (mAbs) against SARS-CoV-2 spike protein from 4 sources. We identified 4 human mAbs with ACE2-like catalytic activity. The activity was not inhibited by MLN-4760, a compound that inhibits native human ACE2, nor by EDTA, unlike native ACE2, a Zinc metalloprotease, but was inhibited by an overlapping pool of Spike peptides. Enzyme kinetic studies showed that the mAbs had lower Vmax and Km values than ACE2. The data suggested that the antibodies cleave angiotensin II via a different mechanism than ACE2. Identification of mAbs with ACE2-like catalytic activity supports the hypothesis that antibodies induced by SARS-CoV-2 infection could help mediate the pathogenesis of COVID-19 and LC, and more generally, the hypothesis that catalytic antibodies induced by infectious agents can contribute to disease pathogenesis.

The ubiquitin conjugating enzyme UBE2J1/Ubc6e localizes to the endoplasmic reticulum where it mediates the ubiquitination and proteasomal degradation of terminally misfolded proteins. Although the protein is known to undergo phosphorylation at serine S184, we have considered modification at an additional site and used a bespoke anti-phospho antibody to confirm phosphorylation also at serine residue S266. Despite the well-described role of UBE2J1 in ER associated degradation (ERAD), we found no evidence for regulation at S266 during Unfolded Protein Response (UPR) induction by thapsigargin. Instead, our studies suggest that phosphorylation occurs independently at the S184 and S266 sites, with mutation at one site failing to disrupt basal phosphorylation at the second. We identified several contexts in which these two phosphorylations were differentially regulated. For example, ER localization, which is important for phosphorylation at S184, was not required for modification at S266, and sensitivity to proteasome inhibitors, which is regarded as a distinguishing feature of the S184 phospho-variant, was unaltered by the S266A mutation. Regarding regulation at S266 on the other hand, we found that pharmacological activation of protein kinase A resulted in rapid phosphorylation, with differential use of phospho-specific antibodies confirming that phosphorylation at S184 was unchanged by this treatment. Hormonal stimulation by glucagon resulted in a similar pattern of UBE2J1 phosphorylation, which occurred exclusively at S266 and could be inhibited by H89. The differential regulation demonstrated in these studies extends our understanding of the UBE2J1 enzyme, and may indicate a role in the integration of energy metabolism with environmental stress conditions.

The enzyme nitric oxide synthase (NOS) breaks down the semi-essential amino acid L-arginine (L-Arg) in the cell to produce citrulline and nitric oxide (NO). NO is a crucial signalling molecule in cells that controls the metabolism of fats and carbohydrates. The aim of this study was to investigate two important genes in the L-Arg-NOS-NO signalling pathway, AMPK and ACC-1, as markers of the molecular mechanisms that are triggered when liver cells sense elevated L-Arg. Mouse liver epithelial insulin-sensitive BNL CL2 cells were used as a model system and cultured with 0, 400 or 800 {micro}M L-Arg. Cell growth parameters were analysed alongside qRT-PCR based analysis of target transcripts involved in lipid and glucose metabolic pathways. In a further experiment, NOS inhibitor; L-NAME (40 mM) and external NO donor; SNAP (100 {micro}M) were added and the effect on target gene expression analysed. L-Arg addition impacted culture viability and cell growth. AMP-activated protein kinase (AMPK) was regulated in response to L-Arg addition with increasing extracellular concentrations elevating AMPK mRNA and protein expressions. L-NAME decreased target gene expression in an L-Arg addition dependent manner. SNAP (100 {micro}M) addition increased target gene expression after 6 and 24 h. NO, produced as a result of L-Arg addition and the factors L-NAME and SNAP, that regulate NO bioavailability, impacted BNL CL2 cell NO/AMPK/ACC-1 signalling pathways via regulating mRNA expression and subsequently protein expression.

It has been recognized a long time ago that the hedgehog (Hh) and Wnt signaling pathways have numerous similarities that suggest their common evolutionary origin. Although the Hh and Wnt proteins are unrelated they are similar in as much as they carry lipid modifications that are critical for their interaction with their receptors. In our earlier work we have shown that Wnt inhibitory factor 1 (WIF1), originally identified as a Wnt antagonist also binds to and inhibits the signaling activity of sonic hedgehog (Shh), raising the possibility that the lipid moieties of these unrelated morphogens play a dominant role in their interaction with WIF1. In the present work we have compared the interactions of human WIF1 protein with lipidated and non-lipidated forms of human sonic hedgehog (Shh) using Surface Plasmon Resonance spectroscopy and reporter assays monitoring the signaling activity of human Shh. Our studies have shown that human WIF1 protein has significantly higher affinity for lipidated than non-lipidated Shh, indicating that lipid modifications of Hhs are important for interactions with WIF1.

Sugar-induced cell death (SICD) remains an intriguing but poorly studied phenomenon in the physiology of Saccharomyces cerevisiae. Recently, it was shown that SICD development largely depends on the redirection of glucose fluxes between glycolysis and the pentose phosphate pathway (PPP). In particular, inhibition of glycolysis by iodoacetamide (IAA) was observed to reduce SICD levels. This study is devoted to further investigation of the relationship between SICD and the functionality of the two PPP branches. It was shown that deletion of the ZWF1 gene does not affect the decrease in SICD levels in IAA-treated cells. This allows us to conclude that the oxidative branch of the PPP is not involved in the suppression of SICD/ROS. Deletion of the GLR1 gene and attenuation of the TRR1 gene also did not restore SICD levels in cells after IAA treatment. The obtained results indicate that the level of reduced glutathione or thioredoxin does not affect SICD genesis. The addition of 5 mM ribose-5-phosphate (R5P) to the incubation medium led to suppression of SICD by 79%. At the same time, the addition of 5 mM ribose + 5 mM Pi suppressed SICD by only 20%. Suppression of SICD by 5 mM R5P in the{Delta} pho3 strain (83%) excludes the mechanism of extracellular dephosphorylation of R5P to ribose, its subsequent transport into the cell, and re-phosphorylation inside the cell. Furthermore, more than 70% suppression of SICD in the{Delta} end3 strain with 5 mM R5P excludes endocytosis as a mechanism of R5P import into the cell. The observed effect of R5P can be explained by the moonlighting function of some unknown protein. Thus, SICD development in S. cerevisiae cells depends on the final product of the non-oxidative PPP--R5P.

The MYC associated factor X (MAX) is the heterodimeric partner of the MYC paralogs (MYC, MYCN and MYCL). When deregulated, high level of the MYC paralogs contribute to all aspects of tumorigenesis and tumor growth. MAX can also heterodimerize with the MXD proteins, MNT and MGA. Heterodimerization and sequence specific DNA binding to the E-Box sequences at gene promoters is controlled by their heterodimerization with the MAX b-HLH-LZ. As a heterodimer with MAX, MYC proteins activate genes involved in cell metabolism, growth and proliferation whereas MXD proteins, MNT and MGA repress them. MAX can also bind to the E-Bos sequence as a homodimer. Being devoid of a transactivation domain it can act as an antagonist of the MYC/MAX heterodimers. Variants of MAX have been reported to be linked to cancer. These variants are either not expressed, inactivated or lead to missense mutations. This has led to the notion that MAX may have a tumor suppressor role. Here, we characterize three of those variants with missense mutations in the basic region, i.e. E32K, R35P and R35C. We analyzed their heterodimerization with the b-HLH-LZ of MYC and their DNA binding properties as homo-and heterodimers. The R35C variant b-HLH-LZ was found to have a markedly increased affinity for the b-HLH-LZ of MYC. We also observed that all three b-HLH-LZ variants have a lower affinity as homodimers for the E-Box than the WT. This was shown to lead to a preferential binding of all the heterodimeric b-LHLH-LZ to the E-Box. This effect is exacerbated in the case of the R35C variant. We argue that this preferential binding of MYC as heterodimers with these variants to E-Box sequences could contribute to tumorigenesis. Hence, our results suggest that, mechanistically, the MAX homodimer bound to the E-Box could act as a tumor suppressor. MATERIALS AND METHODSO_ST_ABSMolecular modelingC_ST_ABSThe open source version 1.7.6.0 of Pymol was used for modeling and molecular rendering [1]. The crystal structure of the MAX homodimer bound to the E-Box (1HLO [2]) was used as a template for the generation of the models. The variants were generated using the mutagenesis function in the wizard. The conformation of the K32 side chain was manually set in order to avoid introducing steric clashes with DNA. Protein expression and purificationThe cDNA, coding for the MAX b-HLH-LZ (Max* hereafter, residues 22-103, UniProt entry P61244-1) to which are added the GSGC residues in c-terminal, inserted in the pET3a vector was already available in the laboratory [3] and was used as a template to generate the plasmids with inserts coding for each of the mutants (E32K, R35C and R35P) through quick-change PCR with Q5 DNA polymerase and DpnI from New England Biolabs. The primers used were purchased from IDT DNA, their sequences are listed in Table S1. Sequence for each construct was confirmed by Sanger sequencing at the Plateforme de sequencage SANGER - Centre de recherche du CHU de Quebec - Universite Laval. The primary structure for the basic region of each construct is given in Fig. 2A. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=137 SRC="FIGDIR/small/715400v1_fig2.gif" ALT="Figure 2"> View larger version (41K): org.highwire.dtl.DTLVardef@1b05d5eorg.highwire.dtl.DTLVardef@1c1d692org.highwire.dtl.DTLVardef@ee469dorg.highwire.dtl.DTLVardef@15e0ba4_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOFigure 2.C_FLOATNO Structure schematics, specific and non-specific interactions dictating specificity and stability of binding of the basic region of MAX to the canonical (CACGTG) E-Box. A. Primary structure for the basic region of MAX and each of the variants. Positions making the most important contacts with the E-box are indicated by black arrows. Positions for the variants studied here are colored according to the Zappo colour scheme, following their physico-chemical properties: red for negative, blue for positive, magenta for proline and yellow for cysteine. B. The side chain (carboxylate) of E32 receives H-Bonds from the CA nucleobases in the leading strand (white carbon atoms). R35 and R36 make a salt bridges with phosphate groups while and the guanidino moiety of R36 makes a specific H-Bond with the nucleobase of the G in the strand of the reverse complement (cyan carbon atoms). C. The R35C mutation removes one non-specific salt-bridge at the interface of the complex. D. The aliphatic portion of the K side chain in the E32K variant is unable to accept the H-Bonds from the CA nucleobases and leads to the stabilisation of the complex and the helical structure of the basic region. E. In addition to removing a salt-bride, the Pro residue in the R35P kinks the path of the basic region, prevents the establishment of the specific H-Bonds mandatory for recognition of the E-Box and leads to unfolding of the helical state. C_FIG The MYC b-HLH-LZ (Myc*), the Max*WT b-HLH-LZ and its variants were expressed and purified as previously described [3,4] After lyophilisation, the b-HLH-LZs were kept at -20{degrees}C and solubilised in Myc buffer (50 mM NaCl, 50 mM NaH2PO4 pH 5.5) for Myc* or PBS for Max* at a final concentration of 1 mM before use. Circular dichroismAll circular dichroism (CD) measurements were performed on a Jasco J-810 spectropolarimeter equipped with a Peltier-type thermostat. The instrument was routinely calibrated using an aqueous solution of d-10-(+)-camphorsulfonic acid at 290.5 nm. Samples were prepared as follows: Max* (either WT or a variant) was diluted in 100 {micro}l 2X CD buffer (40 mM KCl, 11.4 mM K2HPO4, 28.6 mM KH2PO4, pH 6.8) and the volume adjusted to 106 {micro}l with PBS. 10 {micro}l TCEP 16 mM were added, and the volume further adjusted to 192 {micro}l with ddH2O before samples were incubated overnight at room temperature. After reduction, Myc* was added and the volume adjusted to 198 {micro}l with Myc buffer (Na2HPO4 0.95 mM, NaH2PO4 49.05 mM, 50 mM NaCl, pH 5.5). The DNA complexes were prepared as follows. After a 10 minutes incubation of the protein samples at room temperature, 0, 1 or 2 {micro}l of 2 mM of specific or non-specific DNA duplexes in 10 mM Tris pH 8.0 were added and the volume adjusted to 200 {micro}l with 10 mM Tris pH 8.0. The strands of the specific probe were: 5-ATT ACC CAC GTG TCC T*AC-3 and 5-GTA GGA CAC GTG GGT* AAT-3 (with the E-box sequence underlined) and the non-specific probe: 5-ATT ACC TCC GGA TCC T*AC-3 and 5-GTA GGA TCC GGA GGT* AAT-3 (Integrated DNA Technologies). Samples were further incubated for 10 minutes at room temperature and transferred to a 1 mm path length quartz cuvette. All spectra were recorded from 250 to 195 nm at 0.1 nm intervals by accumulating 10 spectra at 25 {degrees}C. Thermal denaturations were recorded at 222 nm from 5 to 95 {degrees}C at a heating rate of 1 {degrees}C/min. CD signal for spectra and thermal denaturations was corrected by substracting the signal from corresponding spectra or thermal denaturation either for buffer alone or the appropriate DNA duplex. CD signal was then converted to mean residue ellipticity using the following formula [5]: [{theta}] = {delta} {middle dot} MRW/(10{middle dot}c l) where [{theta}] is the mean residue ellipticity in deg {middle dot} cm2 dmol-1, {delta} is the CD signal in millidegrees, MRW is the mean residue weight, c is the concentration in mg/ml and l is the pathlength in mm. For the heterodimers, the concentration used was the sum of Max* and Myc* and the MRW was determined using a weighted average.

Background: Endometriosis affects approximately 10% of women of reproductive age and is associated with pelvic pain, infertility, and reduced quality of life. Dienogest is widely used for medical management. This study evaluated the effects of dienogest on endometrioma size, serum CA-125 levels, and pelvic pain. Methods: In this retrospective study, medical records of 45 women aged 18-49 years who received oral dienogest (2 mg/day) for at least six months were reviewed. Endometrioma size was assessed by ultrasound, pelvic pain using the Visual Analog Scale (VAS), and serum CA-125 levels from laboratory records. Baseline and six-month values were compared using the Wilcoxon test and correlations were analyzed using Spearman's test. Results: After six months of treatment, significant reductions were observed in endometrioma size and VAS scores (p<0.001) and CA-125 levels (p<0.001) compared with baseline. No significant correlation was found between endometrioma size and VAS scores or CA-125 levels either before or after treatment (p>0.05). A significant negative correlation was identified between patient age and post-treatment endometrioma size (r = -0.320, p<0.05). Conclusion: Six months of dienogest therapy was associated with significant improvements in lesion size, pain, and biochemical markers. Dienogest may represent an effective medical treatment option for symptomatic patients, particularly for those seeking to avoid surgery and preserve ovarian reserve.

Synthetic 6-Br-Q0C10 has been shown to exhibit a partial electron transfer activity of native coenzyme Q in the isolated mitochondria. It reduces energy coupling efficiency by approximately 30%, suggesting that it may be useful in modulating cell growth in tissue culture. Whether or not it behaves in the same way in the whole cells, or animal, however, has not yet been fully examined. Recently we have investigated the effect of 6-Br-Q0C10 across multiple cell lines using three detection methods. Treatment with 6-Br-Q0C10 reduces cell proliferation in all cell lines tested, with different effectiveness. Obesity-related cell lines were the most susceptible, and a pronounced inhibitory effect was also observed in cancer cell lines. These results strengthen the idea of using 6-Br-Q0C10 to manage obesity or to retard the growth of rate cancer cells and thus prolonging life.

This work explores the relationship between glucose uptake by human endothelial cells and infection by Human Herpesvirus 8 (HHV8). The results indicate that HHV8-infected endothelial cells uptake significantly more glucose than uninfected cells. In addition, when the endothelial cells are treated with diabetes type 2 serums (DM2), the uptake of glucose is even greater in HHV8 infected cells, but it is significantly depressed in not-infected cells. The authors conclude that HHV8 infection could play a role in metabolic modifications which characterize DM2 patients.

Background: Despite significant advancements in obstetric care, the incidence of preeclampsia remains a substantial public health challenge, and effective strategies to prevent the disease progression remain limited, particularly in low-resource settings. N-acetylcysteine (NAC), an antioxidant and glutathione precursor, has demonstrated anti-inflammatory and vasodilatory effects, making it a promising candidate for repurposing. However, robust evidence from well-powered randomized controlled trials is lacking. Objective: This study will evaluate the impact of NAC on the time-to-disease progression in pregnant women with early-onset preeclampsia in Lagos, Nigeria. Methods: This is the study protocol for a proof-of-concept, double-blind, randomized, controlled trial to be conducted between April 2026 to July 2028 at the maternity units of the two teaching hospitals in Lagos, Nigeria. At baseline, n=153 sexually active women aged 18 years or older diagnosed with early-onset preeclampsia at 24 to 34 weeks gestation will be randomised to receive either daily oral tablet containing 600 mg of NAC or a placebo tablet that is matched for appearance and the dosing regimen in addition to standard antenatal care from diagnosis (randomisation) until either 34 weeks gestation or delivery, whichever comes first. The primary endpoint is the time-to-progression (in days) of early-onset preeclampsia to severe disease. The data analysis will be conducted on an intention-to-treat basis. Kaplan-Meier estimates with a Log-rank test will be used to calculate and compare the time-to-disease progression for the treatment groups, while Cox proportional hazard models with a backwards conditional method will be used to compare the primary endpoint between the treatment arms while adjusting for other covariates for precision using hazard ratios (HRs) and 95% confidence intervals (95%CIs). Subgroup analyses will also be performed to assess the differential effects of significant covariates on the impact of NAC on disease progression. Statistical significance will be reported as P<0.05. Discussion: This study will evaluate the efficacy of daily oral NAC compared to placebo in treating pregnant women with early-onset preeclampsia. If proven effective, NAC could offer a safe, affordable, and scalable intervention to reduce the burden of preeclampsia, particularly in resource-constrained settings.

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations in the TSC1 and TSC2 genes and is characterized by benign hamartoma formation in multiple organs. The TSC1-TSC2 complex regulates mTORC1 signaling in response to cellular growth conditions. This study aims to predict the structural stability and functional effects of non-synonymous single-nucleotide polymorphisms (nsSNPs) in human TSC1 and TSC2 using computational approaches. Twelve computational tools were assessed using receiver operating characteristic (ROC) analysis and applied to identify deleterious nsSNPs. Protein stability was predicted using I-Mutant 2.0 and MUpro, while evolutionary conservation was analyzed with ConSurf. NetPhos 3.1 identified potential PTM sites, and MutPred2.0 evaluated their functional impact. Project HOPE assessed mutation-induced physicochemical changes. Structural models were validated using multiple tools, visualized in ChimeraX 1.9, and further evaluated by molecular dynamics simulation to confirm wild-type and mutant stability. All twelve tools had AUC values above 0.90. A combined in silico analysis identified twelve high-risk nsSNPs in TSC1 and sixteen in TSC2, all reducing protein stability, located in conserved regions, and potentially disrupting phosphorylation sites. MutPred and Project HOPE confirmed their impact on protein function. Functional analysis showed TSC1 and TSC2 affect mTORC1 and PI3K-Akt pathways. RMSF and RMSD analyses revealed that TSC1 variants rs1846545280 (G236E), and rs2132135678 (V234E), and TSC2 variants rs45517223 (S758C), rs2151354925 (T836P), and rs45517365 (R1570W) had the largest structural fluctuations. Substitution with glutamic acid, a negatively charged and bulkier residue, may disrupt local folding of TSC1. Similarly, replacement of arginine with tyrosine at position 1570 may impair Rheb binding at the GAP domain of TSC2. These findings highlight potentially pathogenic nsSNPs in TSC1 and TSC2.

BackgroundWhen the skin wound defect is too large, it is difficult for the body to heal itself, and medical treatment is often needed. How to shorten the healing cycle and reduce the incidence of infection is a difficult problem faced by clinicians. Panax notoginseng(PN), a traditional Chinese medicine, can promote the absorption of inflammatory exudates, granulation tissue formation and epidermal proliferation, effectively inhibit the inflammatory reaction of wounds and promote the healing of skin wounds, but its molecular mechanism has not been fully clarified so far. Based on network pharmacology and animal experiments, this study explored the target and molecular mechanism of PN in the treatment of skin wound. MethodsThe active components and potential targets of PN were obtained from the Traditional Chinese Medicine System Pharmacology Database and Analysis Platform (TCMSP) and UniProt database, and the skin wound-related targets were obtained from the GeneCards database. The intersecting targets were filtered using Venny 2.1.0. The intersecting targets were imported into the STRING database to construct a protein-protein interaction (PPI) network. Cluster analysis was performed using the MCODE and CytoHubba plugins in Cytoscape 3.8.2 to obtain core functional network modules and the top 10 key target genes. The intersecting targets were subjected to KEGG and GO enrichment analysis using the DAVID 6.8 database (https://david.ncifcrf.gov/). The component-target-pathway network of PN in the treatment of skin wounds was constructed using Cytoscape 3.8.2 software. In the experimental verification phase, 48 Sprague-Dawley (SD) rats were randomly divided into a control group and a PN group, with 24 rats in each group. A full-thickness skin excision was performed to establish a wound model. The PN group received intraperitoneal injections of the drug, while the control group received an equivalent amount of saline. Wound area measurements were taken on days 1, 4, and 7 after model establishment. Histopathological changes in the injured area and the expression and localization of TNF-, IL-6, and IL-10 were observed through hematoxylin and eosin (HE) staining and immunohistochemical staining. Relative expression levels of the three factors were detected using quantitative real-time polymerase chain reaction (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA). ResultsThis study identified 8 major active components, 156 targets, and 115 signaling pathways involved in the treatment of skin wounds in rats using PN. The top 10 core target genes included TNF, IL-6, and IL-10, primarily enriched in signaling pathways such as NF-{kappa}B, MAPK, and JAK-STAT. Animal experiments revealed that at 4 and 7 days post-injury, the wound area in the PN group was significantly smaller than that in the control group (P<0.05). HE staining showed reduced infiltration of neutrophils and inflammatory cells in the injury area at 7 days in the PN group, accompanied by more pronounced fibroblast proliferation and collagen secretion. Molecular detection indicated that TNF-, IL-6, and IL-10 positive reactants were mainly distributed in the cytoplasm and matrix of epidermal cells, inflammatory cells, and fibroblasts in the skin. qRT-PCR and ELISA results showed that TNF- expression in the PN group was significantly lower than that in the control group at 4 and 7 days (P<0.01). IL-6 expression was lower than that in the control group at all time points, peaking at 4 days and then decreasing (P<0.01). IL-10 expression was significantly lower than that in the control group at 1 and 7 days (P<0.01). ConclusionPN exhibits characteristics such as multi-component, multi-target, multi-pathway synergy, and multiple regulatory pathways in the treatment of skin wounds. It can reshape the dynamic balance of cytokine networks, including TNF-, IL-6, and IL-10, optimize the temporal progression of "inflammation initiation - repair transition - tissue remodeling", and provide a therapeutic effect of "efficient debridement - orderly repair - low scar risk" for skin wounds. It is one of the ideal natural drugs for regulating skin wound healing.

Insulin resistance, excessive and ectopic fat accumulation, chronic low-grade inflammation, and pancreatic beta-cell failure are pathological features of type 2 diabetes mellitus.MiR-130a has been demonstrated to suppress the mRNA levels of PPAR{gamma}, NF-{kappa}B, and TNF- in vitro. PPAR{gamma} is a master regulator of systemic fat and glucose metabolism. NF-{kappa}B and TNF- are pivotal modulators of inflammation. Therefore, we aimed to examine the systemic effect of miR130a on fat metabolism, glucose/insulin homeostasis, and inflammation in mice. We found that mirR130a-deficient mice exhibited larger white fat mass with hypertrophic adipocytes, increased lipogenic gene expression in fat, and elevated serum leptin levels than controls. The white fat pads of mirR130a-deficient mice showed significant macrophage infiltration with enhanced expression of pro-inflammatory genes. In addition, mirR130a-deficient mice had more severe hepatic steatosis and higher hepatic triglycerides content than controls. Similarly, mirR130a-deficient mice had increased macrophage infiltration and lipogenic and inflammatory gene expression in the liver. Consistently, we found that Lepob/ob mice expressed markedly decreased miR130a expression in the liver and white fat compared to controls. Importantly, mirR130a-deficient mice displayed impaired glucose tolerance and worsened insulin resistance, accompanied with reduced serum adiponectin levels. Furthermore, insulin secretion is reduced in mirR130a-deficient mice compared to controls. In conclusion, knockout of miR130a in mice results in fat hypertrophy, hepatic steatosis, increased macrophage infiltration in liver and fat, glucose intolerance, and insulin resistance. These data indicate miR130a exert systemic anti-diabetic effects.

BackgroundMenopausal obesity is a type of obesity in women during menopause where the decline of ovarian function and the decrease of estrogen levels lead to an imbalance between energy intake and consumption in the body, resulting in fat accumulation and weight gain. Moxibustion, as a green therapy of non-interventional external treatment that prevents and treats diseases through thermal stimulation of relevant acupoints, has been widely used in clinical practice because of its simplicity, convenience, effectiveness, low price and high compliance. PurposeTo clarify the pathogenesis of menopausal obesity and the biological mechanism of moxibustion treatment for menopausal obesity. MethodsWe selected 9 plasma samples from menopausal obese patients before and after moxibustion treatment, as well as 9 plasma samples from the healthy control group. After sample mixing and replication, DIA quantitative proteomics analysis was used to screen out differentially expressed proteins, and bioinformatics analysis was conducted. ResultsThe plasma proteomic analysis revealed a significant increase in the protein expression levels of APOC2 and PZP in menopausal obesity patients. These differential proteins primarily participate in biological regulation, cell metabolism, and reproductive development processes. Their biological processes and molecular functions are mainly associated with enzyme inhibitor activity, calcium-dependent protein binding, lipid localization, and plasma lipoprotein particle assembly. The pathogenesis of menopause obesity is linked to the accumulation of visceral fat resulting from changes in sex hormone levels and reduced energy consumption following the decline of female ovarian function. Following moxibustion treatment, there was a notable down-regulation in the plasma levels of sialoglycoprotein receptor 2 (ASGR2), membranin A1 (ANXA1), and human heterogeneous nuclear ribonucleoprotein C (HNRNPC) among menopausal obesity patients. Their biological processes and molecular functions were primarily concentrated on intracellular hagy, nucleic acid binding, tissue regeneration, and neutrophil clearance. ConclusionThe mechanism underlying moxibustions effectiveness in treating menopausal obesity may involve down-regulating HNRNPC expression, activating the PI3K/Akt/mTOR autophagy signaling pathway, regulating hormone levels to delay ovarian aging thereby improving lipid metabolism.

BackgroundUterine atony ([~]70%), lacerations ([~]20%) and placenta-related problems ([~]10%) are assumed main reasons for postpartum hemorrhage genesis. Coagulation components predictive for postpartum blood loss can be identified prepartum and before traditionally assumed main reasons are observed. ObjectivesTo better understand postpartum hemorrhage genesis, we prospectively researched prepartum clinical information, presence of assumed main reasons and peripartum coagulation changes in parturient women. Study designIn 676 women with vaginal deliveries, age, BMI, parity, gestation age, duration of second stage of labor and presence and type of assumed main reasons (uterine atony, lacerations and placenta-related problems) were recorded. Measured blood loss within 24h postpartum defined no, non-severe or severe PPH (<500ml, [&ge;]500ml to <1000ml, [&ge;]1000ml). Hemoglobin, platelet count, fibrinogen, factor II and factor XIII activity were measured at admission and 24-48h postpartum. ResultsOf 191 women developing postpartum hemorrhage, 53.9% did not show assumed main reasons (expected <5%, p<.001). Of 45 women with severe postpartum hemorrhage, 15.5% were without assumed main reasons (<5%, p<.001). Sole atony occurred less frequently than expected (8.2% in non-severe and 35.5% in severe PPH, p<.001). FXIII showed the largest decrease of coagulation factors by far, from no (-12%) to non-severe (-20%) and severe postpartum hemorrhage (-32%, p<.001). Duration of the second stage of labor was longer in women developing postpartum hemorrhage later on (71 vs. 46 minutes, p=.004), but was not different between women with or without assumed main reasons. ConclusionUterine atony frequency is low in non-severe postpartum hemorrhage, but progresses from non-severe to severe postpartum hemorrhage. It can thus not be the frequent reason for postpartum hemorrhage it is assumed to be, as all postpartum hemorrhages start as non-severe. A prolonged second stage of labor together with an ongoing (likely self-reinforcing) consumptive coagulopathy helps to explain postpartum hemorrhage genesis. FXIII is a prepartum predictor of postpartum blood loss and shows the most pronounced peripartum coagulation factor loss in any setting. This might allow to identify new treatment pathways.

ObjectiveTo explore the application value of dual-staining for specific AT sequence binding protein 2 (SATB2) immunohistochemistry and elastic lamina in detecting elastic lamina invasion (ELI) in pT3 colon cancer, and to assess its association with clinicopathological characteristics, staging, and prognosis. MethodsThis retrospective cohort study enrolled 176 pT3 colon cancer patients who underwent radical resection at Affiliated Jinhua Hospital Zhejiang University School of Medicine. The deepest tumor-infiltrated paraffin blocks were collected for SATB2 immunohistochemistry and elastin dual-staining. Correlations between ELI status and clinicopathological characteristics and prognosis were analyzed. Survival data of 74 pT4a stage patients were collected for comparative analysis. ResultsELI (+) was positively associated with high tumor budding grade, vascular invasion, lymph node metastasis, and reduced tumor infiltrating lymphocytes (TILs) (all P < 0.001). No correlations were observed with age, gender, tumor location, histological subtype, tumor grade, or perineural invasion (all P > 0.05). The ELI (+) group exhibited significantly shorter disease-free survival (DFS) and overall survival (OS) compared to ELI (-) group (P < 0.05). Additionally, the ELI (+) group demonstrated inferior OS than the pT4a group, though DFS did not differ significantly. ConclusionDual-staining of SATB2 immunohistochemistry and elastic lamina provides a reproducible and objective method for assessing ELI. ELI correlates with key clinicopathological features and functions as an independent adverse prognostic indicator in pT3 colon cancer.

Mitochondria are essential for metabolic homeostasis and neuronal function, extending beyond ATP production to roles in cell signaling, inflammation, and stress responses. Mitochondrial dysfunction, marked by abnormal morphology, ATP deficiency, and oxidative stress, is a key feature of aging-related diseases and neurodegenerative disorders like Parkinsons. Given the importance of mitochondrial homeostasis to brain function, this study aimed to determine the possible vitamin D (VD3) effects on mitochondrial susceptibility to Ca2+-induced mitochondrial permeability transition pore (mPTP), bioenergetics in brain mitochondria, and redox balance. We demonstrated that VD3 protects isolated brain mitochondria. Male rats were divided into control and VD3-treated groups. Brain mitochondria were isolated for assessments of Ca2+-induced mitochondrial swelling secondary to MPTP opening, oxygen consumption (states 3 - ADP-stimulated and state 4 - in the presence of oligomycin), and the respiratory control ratio (RCR). Oxidative stress parameters (nitrite and lipid peroxidation), superoxide dismutase (SOD) activity, and reduced glutathione (GSH) levels were also evaluated. The results revealed that VD3 treatment blocked Ca2+-induced mitochondrial swelling secondary to MPTP opening. Additionally, VD3 improved mitochondrial RCR compared to controls, in the presence of complex I (malate/glutamate) and complex II (succinate) substrates, reduced mitochondrial succinate-driven H2O2 release, and enhanced SOD activity and GSH levels. These changes occurred in parallel with decreased nitrite and TBARS formation. These results suggest that vitamin D{square} confers mitochondrial neuroprotection, emphasizing its prospective role in maintaining neuronal homeostasis and mitigating neurodegenerative processes.

The objective of this research was to characterize the proteome of the Apis mellifera royal pupae to evaluate its potential as a nutraceutical and functional food. Six pupal instars (E1-E6) were analyzed using liquid chromatography, mass spectrometry, and bioinformatics techniques to determine their properties and biological functions. The results showed 15 proteins across the different instars. In E1, the Isoform X2 of the Caf1 protein and the vitellogenin precursor were found, both critical in genetic regulation and nutrient transport. E2 revealed three proteins linked to energy and genetic processes. Proteins identified in E3 were associated with sugar metabolism and cellular structure. E4 presented proteins related to cellular stress and oxidative processes. In E5, three proteins were identified, associated with molecular transport and energy metabolism. Results for instar E6 were inconclusive since the complexity of peptide identification. From a nutraceutical and functional perspective, the identified proteins show significant potential due to their antioxidant activities, metabolic control, and cellular regulation. Noteworthy proteins include aldose reductase for its role in diabetes management, glutamate dehydrogenase for its importance in amino acid metabolism, vitellogenin as a nutrient source and immune system stimulant, and heat shock protein 60 A, with therapeutic potential in cardiovascular diseases.